AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05595447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin 50 MG [Adcetris]
Description: Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1
Study NCT05394948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary recommendations including experimental nutraceutic.
Description: Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the experimental nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
Study NCT05394948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary recommendations including control nutraceutic.
Description: Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the control nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
Study NCT05141773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed adenoma detection system (CADe) plus endocuff
Description: This is a computed system that helps the endoscopist to increase the detection of colorectal polyps. An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
Study NCT05141773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff
Description: An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
Study NCT05293795 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 3D printed model
Description: Mother is given 3D printed model of fetus' face
Study NCT05293795 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mother is given a picture of 3D ultrasound of fetus
Study NCT04713800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR-TiB)
Description: In group ZR-TiB the implant impressions will be taken using an intra-oral scanner and the respective scanbody. The restorations will be manufactured by means of CAD/CAM procedures using monolithic zirconia. For sufficient aesthetics, the zirconia restorations can be manually veneered with veneering ceramic only at the buccal surface, while the occlusal surface will remain monolithic and will be high-gloss polished. The zirconia restorations will be extra-orally cemented onto titanium base abutments (Straumann® Variobase® for crown, Straumann AG), correctly polished and delivered to the patient, by screw-retention onto the implant.
Study NCT04713800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM-GA)
Description: In group PFM-GA implant impression will be taken using a polyvinyl siloxane or polyether impression material in a conventional manner with the use of stock trays and corresponding impression copings. The framework will be manufactured by the lost wax-technique using a gold-abutment (Straumann® Gold abutment for crown, Straumann AG) and a gold-alloy. All metal frameworks will be manually veneered with veneering ceramic, polished and glazed, and delivered to the patient, by screw-retention onto the implant.
Study NCT06327581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: patients will be treated with MN combined with lactic acid solution 1%. Lactic acid solution 88% concentration PH (6.84), diluted with distilled water to have a final concentration of 1%
Study NCT05284175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib, orally, 50 mg QD
Study NCT06327581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vit D
Description: patients will be treated with MN combined with topical application of vitamin D3 (an aqueous preparation of cholecalciferol (2.5 mg/ ml), The maximum total amount of vitamin D3 injected into a patient in every session will be 2.5 mg (1 ml)
Study NCT06327581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area
Study NCT06327581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: patients will be treated with MN combined with normal saline 0.9%
Study NCT05446467 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: pembrolizumab+cisplatin + 5-FU
Description: ivgtt, pembrolizumab 200mg d1+cisplatin20 mg/m2 qd d1-d3 + 5-fluorouracil 3000mg/m2 last for 120hours, six circles. Subjects will undergo surgery after receiving neoadjuvant chemotherapy within 3 weeks, followed by adjuvant therapy and pembrolizumab alone maintenance treatment.
Study NCT05271474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANNE ONE Platform
Description: ANNE ONE is one most advanced digital platforms that are gradually becoming more available to enable providers to help patients manage their condition. It integrates soft and flexible sensors for comprehensive vital signs monitoring. This platform creates objective transparency by automatically recording data from the sensor on the patient, lessening the need for patients to consciously track their COPD exacerbation events, enabling providers to proactively manage their patients' condition, and creating actionable reports for providers to review with their patients.
Study NCT06495814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1/bag of Jinlida granules, 3 times/day, taken with hot water.
Description: All observation and intervention groups received lifestyle interventions, with only the intervention group of high-risk obese impaired glucose tolerance receiving intervention with Jinlida granules.
Study NCT05329805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: job crafting intervention
Description: the participated nurses will receive session about job crafting followed by activity related to job crafting
Study NCT04601870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Financial Incentive
Description: No monetary incentive to participate in quit planning and quit counseling with a tobacco cessation specialist.
Study NCT04601870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive (100 dollars)
Description: Financial incentive (100 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
Study NCT04601870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive (50 dollars)
Description: Financial incentive (50 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
Study NCT05686538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iDLI
Description: TCRab/CD19 depleted DLI 14 days after allogeneic stem cell transplantation. Targeted cell doses: >10e7 NK cells/kg and >10e6 TCRgd cells/kg
Study NCT05810259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caravan Wellness app
Description: Caravan Wellness is a digital platform that offers brief mindfulness and light to moderate physical activity modules, among many others (e.g., Pilates, Yoga, Barre, meditation, etc.), to enhance overall individual well-being.
Study NCT04887779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pathologist intervention
Description: viewing explanted organ and microscopy
Study NCT04847232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Description: Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the long interdialytic interval (LIDI).
Study NCT04847232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SZC Placebo
Description: Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the LIDI.
Study NCT04861792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Michigan SPARC Quality Improvement Intervention
Description: Practice facilitation, electronic health record (EHR) support, performance monitoring and feedback combined with alcohol-related continuing medical education (CME) and maintenance of certification (MOC) and tools to support alcohol related care including a decision aid for shared decision making about alcohol use disorder (AUD).
Study NCT06093334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-field magnetic resonance imaging
Description: Imaging of lung parenchyma and function by LF-MRI
Study NCT06093334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary testing
Description: Myocardial function (Strain-Analysis by echocardiography) and spiroergometry, capillary blood gases and lactate
Study NCT06093334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulmonary testing
Description: Lung function (VC%, FEV1%)
Study NCT06093334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Standard procedures/parameters routinely available in follow-up care after oncological treatment
Study NCT06550921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation of oligometastasis
Description: The oligometastasis of hepatocellular carcinoma are ablation completely by ablation (including microwave ablation, radiofrequency ablation, and cryoablation)
Study NCT04640116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Description: A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents (GORE® VIATORR) were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the patients received a diuretic treatment and a salt-limited diet until the ascites disappeared.
Study NCT04640116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation (MWA)
Description: MWA: After the patient's ascites disappears, MWA therapy will be performed. A MWA antenna was gradually inserted into the tumor along the predetermined angle under the guidance of Computed Tomography (CT). The whole thermal procedure was conducted under intravenous anesthesia. Vital signs were monitored during the procedure. The settings of the ablation parameters depended upon the manufacturer's recommendation and our experience. Ablation volume was determined by physicians according to liver function, tumor invasion site, and tumor stage. An upper abdominal CT scan was carried out immediately after the procedure to evaluate the ablation area and complications.
Study NCT05545501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Salt, No β-OHB
Description: Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
Study NCT05545501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Salt, No β-OHB
Description: Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
Study NCT05545501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Salt, High β-OHB
Description: Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
Study NCT06144372 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electroconductive and Electrohydraulic types
Description: The patients were randomly assigned to two types of lithotripter.
Study NCT06181149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delaying speech initiation
Description: This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use transcranial magnetic stimulation to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
Study NCT06181149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory errors and pre-speech auditory modulation
Description: This intervention will examine the contributions of auditory errors to pre-speech auditory modulation. Participants will receive auditory perturbations while speaking, and we will collect their brain activities throughout the study.
Study NCT06181149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contributions of the speech premotor cortex to pre-speech auditory modulation
Description: This intervention will examine the effects of stimulation of the left ventral premotor cortex on pre-speech auditory modulation. Participants will receive electrical stimulation while speaking.
Study NCT06181149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delaying auditory feedback
Description: This intervention will examine the effects of misalignment between prediction and auditory feedback in participants. We will use delayed auditory feedback to induce a temporal misalignment between prediction and auditory feedback while participants produce speech.
Study NCT04725669 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ELISA IgG Testkit
Description: All samples will be tested for IgG antibody level to pertussis toxin using a commercial Bordetella pertussis ELISA IgG Testkit in accordance to the manufacturers' protocol in the laboratory at the University Hospital for Infectious Diseases in Zagreb.
Study NCT05719961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS062 injection
Description: Part I: A single dose of 1.2noml/kg is administered.
Study NCT05719961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Part I: A single dose of 0.2U/kg is administered.
Study NCT05719961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR20014 injection
Description: Part II: Ascending single doses at three dose levels
Study NCT05719961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart 30 Injection
Description: Part II: A single dosewas administered
Study NCT04814641 — intervention group
Intervention type: BIOLOGICAL
Intervention: hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit
Description: Serum phosphorus level \< 1.55 mmol/L at any time between admission and the 5th day.
Study NCT05854095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pivot Bridge
Description: transcatheter for short-term treat Functional Tricuspid regurgitation
Study NCT05019677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+PD-1+Tight
Description: Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W
Study NCT06305845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital crowns
Description: crowns fabricated digitally by CAD-CAM technology
Study NCT06305845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zirconia crowns
Description: crowns that are ready made for primary teeth
Study NCT06060470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based dance group
Description: Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists.
Study NCT06060470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Control
Description: Participants in the control group will receive current standard of care: education on conventional exercise and fall prevention programs. The control and intervention groups will have the same duration of 10 weeks (1session/week), while the format of the contact (Tele) and session time of the contact will be proportional to the content delivered (30-45 minutes/session) in the control group; 80-90 minutes in the intervention group). Participants, regardless of randomization, will complete assessments and follow-ups with blinded outcome assessors.
Study NCT06274827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Superficial Electromyography
Description: For all MVICs, five seconds of each repetition were included in the analysis and the maximum value of three repetitions was taken. For all exercises, the middle 3 seconds of the 5 second data collection period were included in the analysis and the average muscle activation level of the three repetitions was recorded. The average signal amplitude of each exercise was divided by the MVIC of each muscle of interest to obtain the %MVIC value.
Study NCT06550323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group using virtual reality glasses
Description: Group using virtual reality glasses: During the procedure, individuals will wear glasses.
Study NCT05786313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Centerpiece titanium plate
Description: All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.
Study NCT05786313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Centerpiece titanium plate
Description: All indexes were collected from the patients with Centerpiece titanium plate for internal fixation.
Study NCT05991375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXmedetomidine
Description: 28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL
Study NCT05991375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: 28 mL of Bupivacain 0.25% was mixed with 2 mL of Normal saline = total volume 30 mL
Study NCT05767385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Arm
Description: * Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care.~* Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete.~* Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline.
Study NCT05928351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: The experimental group will follow a PNE protocol based on previous procedure for 6 weeks in addition to the standard physiotherapy program (SPP) in postoperative period.~Each PNE session will take 45-60 min. PNE will be conducted in line with international guidelines and covered the neurophysiology of pain, transition from acute to chronic pain, and the nervous system ability to modulate the pain experience.
Study NCT05928351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Program (SPP)
Description: The control group will follow a SPP. The 45-minute-long treatment sessions will be held 5 days per week. The treatment program will be organized in 3 periods as 0-2 weeks, 3-4 weeks and 5-6 weeks. The overall treatment program will include scar massage, patellar mobilization, coldpack, ankle pump, quadriceps and hamstring strengthening, hip range of motion, hip strengthening exercises, squat, ascending and descending stairs, walking training. All exercises will be 10 repetitions x 2 sets.
Study NCT05928351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Program (SPP)
Description: The control group will follow a SPP. The 45-minute-long treatment sessions will be held 5 days per week. The treatment program will be organized in 3 periods as 0-2 weeks, 3-4 weeks and 5-6 weeks. The overall treatment program will include scar massage, patellar mobilization, coldpack, ankle pump, quadriceps and hamstring strengthening, hip range of motion, hip strengthening exercises, squat, ascending and descending stairs, walking training. All exercises will be 10 repetitions x 2 sets.